Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KLK7 | P49862 | 2/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400712 | 1.00 | TDP1 (0.48) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL3754005 | 1.00 | TDP1 (0.48) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL12604209 | 0.97 | MEN1 (0.48) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL30895563 | 0.97 | MEN1 (0.48) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL18206801 | 0.94 | CA1 (0.49) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL18206800 | 0.94 | CA1 (0.49) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL15893373 | 0.93 | TDP1 (0.44) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL18978546 | 0.91 | TDP1 (0.42) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL15698479 | 0.91 | KLK7 (0.40) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL21901505 | 0.91 | MEN1 (0.44) | TDP1ATMPOLBNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-03-26 | — | — | US | disclosed |
| EP-4608451-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| US-20240261427-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-08-08 | — | — | US | disclosed |
| US-20240245796-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-07-25 | — | — | US | disclosed |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-06-27 | — | — | US | disclosed |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| US-20240208896-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | CHATHAM BIOPHARMA CONSULTING, LLC | 2024-06-27 | — | — | US | disclosed |
| WO-2024092067-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2022198114-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | XYZAGEN, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-10690675-B2 | Methods for enriching glycopeptides for global analysis of glycoproteins | GEORGIA TECH RESEARCH CORPORATION (US) | 2020-06-23 | — | — | US | disclosed |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-12-23 | — | — | US | disclosed |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-12-23 | — | — | US | disclosed |
| US-7727713-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2010-06-01 | — | — | US | disclosed |
| US-7727713-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2010-06-01 | — | — | US | disclosed |
| US-20100016177-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20090221684-A1 | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221684-A1 | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-09-03 | — | — | US | disclosed |
| US-20070232576-A1 | Sulfated molecular umbrellas as anti-HIV and anti-HSV agents | LEHIGH UNIVERSITY (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | PPM1D, PPM1G, PPM1F | TDP1 1180/4885ATM 3604/4885POLB 4458/4885 |
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | CD74, HACD3, FCGR2A | TDP1 2600/4885ATM 4801/4885POLB 2401/4885 |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TDP1 3150/4885ATM 4660/4885POLB 3246/4885 |
| US-20240208896-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | KCNA7, KCNB1, KCNB2 | TDP1 2718/4885ATM 3639/4885POLB 1309/4885 |
| US-20070232576-A1 | Sulfated molecular umbrellas as anti-HIV and anti-HSV agents | RPL17, SSU72, RPL27A | TDP1 4298/4885ATM 4586/4885POLB 1193/4885 |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | PPM1F, PPM1D, PPP1R1B | TDP1 1449/4885ATM 3483/4885POLB 3949/4885 |
| US-20100016177-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | INTS6, ABL1, INMT | TDP1 1463/4885ATM 4005/4885POLB 109/4885 |
| US-20090221684-A1 | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | ANXA6, STING1, ADM2 | TDP1 685/4885ATM 1415/4885POLB 761/4885 |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TDP1 3150/4885ATM 4660/4885POLB 3246/4885 |
| US-20240261427-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TDP1 3150/4885ATM 4660/4885POLB 3246/4885 |
| US-10690675-B2 | Methods for enriching glycopeptides for global analysis of glycoproteins | SIGLEC7, SIGLEC9, FUT6 | TDP1 4502/4885ATM 4673/4885POLB 4464/4885 |
| US-20240245796-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TDP1 3150/4885ATM 4660/4885POLB 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.